What are the latest news in the cell therapy market?
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market is moving fast, and the latest news shows how CAR-T, in vivo CAR-T, and other living-cell drugs are becoming more important for drug developers.
We constantly update this blog post so readers can follow the biggest cell therapy market news without needing to read every company press release.
In this article, we focus on the latest market news that matters most for investors, founders, and operators in the cell therapy market.
And if you want to better understand this new industry, you can download our pitch covering the cell therapy market.
Insights
- In vivo CAR-T became the clearest theme in the cell therapy market, with Lilly buying Kelonia and CREATE raising $122 million to push similar technology forward.
- The cell therapy market is not only about oncology anymore, because autoimmune disease programs from CREATE and Fate show how CAR-T could expand beyond cancer.
- Large buyers still want late-stage CAR-T assets, and Gilead’s $7.8 billion Arcellx deal gives the cell therapy market a strong valuation signal.
- Manufacturing remains one of the hardest parts of the cell therapy market, as Orca-T’s FDA delay shows that strong clinical data are not always enough.
- Commercial CAR-T can scale when execution works, and Carvykti’s 62% sales growth is one of the strongest proof points in the cell therapy market.
- Solid-tumor CAR-T remains risky, but Oricell’s large financing and Legend’s early LB2102 data show that the cell therapy market still believes in the opportunity.
- Regulators are still supporting cell therapy products when companies bring strong evidence, as shown by Tecartus receiving full FDA approval in mantle-cell lymphoma.
- Academic manufacturing is becoming more important in the cell therapy market, with Colorado showing that a university campus can move its own CAR-T into clinical testing.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Summary table of the latest news in the cell therapy market
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
You can also read our detailed analysis to understand what are the quarterly updates in the cell therapy market.
| Piece of news | Category | Exact date | Source |
|---|---|---|---|
| Legend showed early solid-tumor CAR-T activity with LB2102 at ASCO. | Success metrics | June 1, 2026 | Legend Biotech |
| Kelonia’s in vivo CAR-T showed responses in all evaluable myeloma patients. | Success metrics | May 31, 2026 | Kelonia |
| CREATE raised $122 million to push in vivo CAR-T into autoimmune disease and cancer. | Fundraisings | May 14, 2026 | CREATE Medicines |
| Legend’s Carvykti sales jumped 62%, showing commercial CAR-T scale. | Financial results | May 12, 2026 | Legend Biotech |
| Fate showed lupus activity for off-the-shelf CAR-T without conditioning chemotherapy. | Success metrics | May 11, 2026 | Fate Therapeutics |
| Gilead closed its $7.8 billion Arcellx deal before anito-cel’s possible launch. | M&A | April 28, 2026 | Business Wire |
| FDA gave Orca-Q RMAT status, helping Orca Bio speed regulatory talks. | Regulations & Policies | April 28, 2026 | Orca Bio |
| Lilly moved to buy Kelonia to simplify CAR-T into an in-body treatment. | M&A | April 20, 2026 | Eli Lilly and Company |
| Oricell raised $110 million before an IPO push for solid-tumor CAR-T. | Fundraisings | April 10, 2026 | Oricell |
| FDA converted Kite’s Tecartus mantle-cell lymphoma approval to full approval. | Regulations & Policies | April 2, 2026 | Gilead |
| Colorado won FDA clearance for the first U.S. campus-built CAR-T trial. | New tech and infrastructure | April 2, 2026 | PR Newswire |
| Orca-T’s FDA review was delayed three months for manufacturing review. | Regulations & Policies | April 1, 2026 | Orca Bio |
| ASGCT and Citeline said cell and gene therapy dealmaking stayed resilient in Q1. | Market Research | April 2026 | ASGCT |
Latest news of the cell therapy market
Legend showed that solid-tumor CAR-T may finally be making early clinical progress.
Success metrics
What happened?
Legend Biotech reported first-in-human data for LB2102, a DLL3-targeted CAR-T therapy for small-cell lung cancer and large-cell neuroendocrine carcinoma. At higher dose levels, Legend Biotech reported a 28.6% objective response rate and a 78.6% disease control rate.
When was it?
Legend Biotech announced the data on June 1, 2026.
Why is it big news?
Solid tumors are one of the hardest areas in the cell therapy market, so even early signs of CAR-T activity matter.
Why should you care?
If you’re an investor in the cell therapy market, Legend Biotech’s data show why solid-tumor CAR-T remains a high-risk but high-upside opportunity.
If you’re an entrepreneur in the cell therapy market, Legend Biotech’s LB2102 data show that focused targets and careful clinical design can still attract attention in solid tumors.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Kelonia’s in vivo CAR-T data supported one of the hottest ideas in cell therapy.
Success metrics
What happened?
Kelonia reported updated Phase 1 data for KLN-1010, an in vivo BCMA CAR-T therapy for multiple myeloma. Kelonia said all evaluable patients had a response, and all had no detectable minimal residual disease in bone marrow one month after treatment.
When was it?
Kelonia announced the updated data on May 31, 2026.
Why is it big news?
The data make the in vivo CAR-T idea easier to understand because the treatment is designed to make CAR-T cells inside the patient’s body.
Why should you care?
If you’re an investor in the cell therapy market, Kelonia’s early data make in vivo CAR-T look more credible as a future growth area.
If you’re an entrepreneur in the cell therapy market, Kelonia’s data show that strong early proof can quickly raise the value of a platform company.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
CREATE raised $122 million as investors backed in vivo CAR-T beyond cancer.
Fundraisings
What happened?
CREATE Medicines raised $122 million in Series B financing. CREATE Medicines plans to use the funding for in vivo CAR-T programs in autoimmune disease and oncology, including CD19 and CD19 x BCMA programs.
When was it?
CREATE Medicines announced the financing on May 14, 2026.
Why is it big news?
The round shows that investors are still willing to fund ambitious cell therapy market platforms when the idea could make CAR-T simpler and broader.
Why should you care?
If you’re an investor in the cell therapy market, CREATE Medicines shows that private capital is moving toward platforms that can produce more than one drug.
If you’re an entrepreneur in the cell therapy market, CREATE Medicines shows that a clear platform story can still raise major money.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Carvykti sales jumped 62%, giving the cell therapy market a major commercial proof point.
Financial results
What happened?
Legend Biotech reported that Carvykti net trade sales reached about $597 million in the first quarter of 2026. Legend Biotech also said Carvykti was available in 18 markets and more than 300 sites.
When was it?
Legend Biotech reported the results on May 12, 2026.
Why is it big news?
Carvykti’s growth shows that a complex CAR-T product can become a large commercial drug when manufacturing and access improve.
Why should you care?
If you’re an investor in the cell therapy market, Carvykti shows that commercial CAR-T can scale beyond a niche product.
If you’re an entrepreneur in the cell therapy market, Carvykti shows that launch execution can become as important as the science.
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
Fate showed lupus activity without conditioning chemotherapy, a key barrier for autoimmune CAR-T.
Success metrics
What happened?
Fate Therapeutics presented data for FT819, an off-the-shelf CAR-T candidate in systemic lupus erythematosus. Fate Therapeutics said a single dose without conditioning chemotherapy achieved low disease activity in active lupus patients.
When was it?
Fate Therapeutics announced the data on May 11, 2026.
Why is it big news?
Conditioning chemotherapy is a major barrier for using cell therapy outside cancer, so a no-conditioning approach could make autoimmune CAR-T easier to use.
Why should you care?
If you’re an investor in the cell therapy market, Fate Therapeutics shows why autoimmune disease could become a major expansion area.
If you’re an entrepreneur in the cell therapy market, Fate Therapeutics shows that convenience and safety can be as important as response rates.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Gilead closed a $7.8 billion Arcellx deal before anito-cel’s possible launch.
M&A
What happened?
Gilead completed the acquisition of Arcellx for about $7.8 billion. The main asset is anito-cel, a BCMA CAR-T therapy for multiple myeloma that could be close to commercial launch.
When was it?
Gilead completed the acquisition on April 28, 2026.
Why is it big news?
The deal shows that large late-stage CAR-T assets can still command very high prices in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, Gilead’s Arcellx deal gives a strong valuation benchmark for late-stage CAR-T companies.
If you’re an entrepreneur in the cell therapy market, Gilead’s Arcellx deal shows that clinical maturity and commercial readiness can create strategic value.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
FDA gave Orca-Q RMAT status, helping Orca Bio strengthen its allogeneic platform.
Regulations & Policies
What happened?
FDA granted RMAT designation to Orca-Q, Orca Bio’s second-generation allogeneic T-cell immunotherapy for high-risk blood cancers. Orca Bio said the designation was based on early Phase 1 data.
When was it?
Orca Bio announced the RMAT designation on April 28, 2026.
Why is it big news?
RMAT status can give Orca Bio closer FDA interaction and may support a faster path through development.
Why should you care?
If you’re an investor in the cell therapy market, Orca-Q’s RMAT status adds regulatory support to Orca Bio’s allogeneic cell therapy strategy.
If you’re an entrepreneur in the cell therapy market, Orca-Q shows that early clinical signals can unlock useful regulatory advantages.
In our cell therapy market deck, we tell you what to focus on
Lilly moved to buy Kelonia, making in vivo CAR-T a top cell therapy market theme.
M&A
What happened?
Lilly agreed to acquire Kelonia, whose lead program KLN-1010 is designed to make CAR-T cells inside the patient’s body. Lilly said the approach could reduce major barriers around manufacturing, safety, and patient access.
When was it?
Lilly announced the agreement on April 20, 2026.
Why is it big news?
The acquisition is a strong sign that large pharma sees in vivo CAR-T as a next wave in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, Lilly’s Kelonia deal shows that strategic buyers value platforms that could make CAR-T easier to deliver.
If you’re an entrepreneur in the cell therapy market, Lilly’s Kelonia deal shows that solving cost, access, and logistics can create major value.
In our cell therapy market deck, we identify pain points entrepreneurs should prioritize
Oricell raised more than $110 million before an IPO push for solid-tumor CAR-T.
Fundraisings
What happened?
Oricell closed more than $110 million in pre-IPO financing. Oricell is developing CAR-T therapies for solid tumors, led by Ori-C101, a GPC3-targeted CAR-T therapy for advanced liver cancer.
When was it?
Oricell announced the financing on April 10, 2026.
Why is it big news?
The financing shows that investors still believe solid tumors can become a major opportunity in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, Oricell shows that solid-tumor CAR-T companies can still raise large rounds.
If you’re an entrepreneur in the cell therapy market, Oricell shows that hard biology can still be fundable when the target and clinical path are clear.
In our cell therapy market deck, we dentify risks investors and builders need to be aware of
FDA gave Tecartus full approval, strengthening confidence in commercial CAR-T.
Regulations & Policies
What happened?
FDA granted full approval to Kite’s Tecartus for adults with relapsed or refractory mantle-cell lymphoma. The decision converted the earlier accelerated approval into a full approval based on confirmatory evidence.
When was it?
Gilead announced the FDA decision on April 2, 2026.
Why is it big news?
Full approval lowers regulatory uncertainty for a marketed CAR-T product and supports long-term confidence in the cell therapy market.
Why should you care?
If you’re an investor in the cell therapy market, Tecartus full approval can support revenue durability and payer confidence.
If you’re an entrepreneur in the cell therapy market, Tecartus shows that confirmatory data remain essential after accelerated approval.
In our cell therapy market deck, we ensure you have the latest information
Colorado received FDA clearance for a campus-built CAR-T clinical trial.
New tech and infrastructure
What happened?
The University of Colorado Anschutz Gates Institute received FDA IND clearance for a CD64-directed CAR-T therapy for relapsed or refractory acute myeloid leukemia. The institution described the therapy as the first U.S. CAR-T authorized for clinical testing that was developed entirely on its campus.
When was it?
The University of Colorado Anschutz Gates Institute announced the FDA clearance on April 2, 2026.
Why is it big news?
The clearance shows that academic and hospital-linked groups can build cell therapy products that move into human testing.
Why should you care?
If you’re an investor in the cell therapy market, academic manufacturing hubs could create new assets and new partnership opportunities.
If you’re an entrepreneur in the cell therapy market, Colorado’s clearance shows that integrated discovery, manufacturing, and clinical testing can be a real advantage.
In our cell therapy market deck, we like to quantify things to make things easier to understand
Orca-T’s FDA review delay showed why manufacturing can decide cell therapy timelines.
Regulations & Policies
What happened?
FDA extended the review of Orca Bio’s BLA for Orca-T to July 6, 2026. Orca Bio said the extension followed updated manufacturing information and that FDA did not ask for more clinical data.
When was it?
Orca Bio announced the FDA review extension on April 1, 2026.
Why is it big news?
The delay shows that manufacturing can change approval timing even when clinical questions are not the main issue.
Why should you care?
If you’re an investor in the cell therapy market, Orca-T’s delay shows why manufacturing readiness affects approval timing and cash needs.
If you’re an entrepreneur in the cell therapy market, Orca-T’s delay shows that CMC work is not back-office work, but part of the core strategy.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
ASGCT and Citeline said cell and gene therapy dealmaking stayed resilient in Q1.
Market Research
What happened?
ASGCT and Citeline’s Q1 2026 landscape report said dealmaking rose 3% to 103 transactions, even as approvals slowed. The report also highlighted major CAR-T acquisitions as evidence of continued confidence in the sector.
When was it?
ASGCT and Citeline published the report in April 2026.
Why is it big news?
The report shows that the cell therapy market is not simply booming or collapsing, but becoming more selective.
Why should you care?
If you’re an investor in the cell therapy market, the ASGCT and Citeline report shows that differentiated and de-risked assets still attract attention.
If you’re an entrepreneur in the cell therapy market, the ASGCT and Citeline report shows that the funding window is open, but stronger proof points matter more.
Related blog posts
- The latest progress in the cell therapy market
- How strong is fundraising in the cell therapy market right now?
- What is the true size of the cell therapy market?
- How funding activity has evolved in the cell therapy market
- What are the key fundraising trends in the cell therapy market?
- A complete list of funding deals in the cell therapy market
- A complete list of business models in the cell therapy market
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
